October 31, 2025 in Press Release

Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 – 9, 2025.

Comments Off on Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunotherapy of Cancer (SITC) Nov. 5 – 9, 2025.

Clinical Data of Two HighField Biopharmaceuticals Immuno-Oncology Lipid-Based Therapeutics Accepted for Late-Breaking Abstract Presentations at the 40th Anniversary Meeting of the Society for Immunoth ...

Read More
April 21, 2025 in Press Release

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs

Comments Off on HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs

HighField Biopharmaceuticals Files INDs for Two ADCplex™ Immunoliposomes with Different Cancer Killing Payloads to Overcome Limitations of Current ADCs The new technology behind HighField’s immu ...

Read More